Annovis Bio's U.S. Patent for TBI Treatment with Buntanetap: Key Questions Answered

What is the significance of Annovis Bio’s new U.S. patent?

The U.S. Patent No. 12,042,482 allows Annovis Bio to treat traumatic brain injury (TBI) with buntanetap, enhancing their portfolio for treating acute and chronic neurodegenerative diseases and mental illnesses.

How does buntanetap work in treating TBI?

Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43, improving synaptic transmission and axonal transport while reducing neuroinflammation.

Why is TBI treatment important?

TBI is a major cause of death and disability in the U.S., with an annual death rate exceeding 70,000, making effective treatments like buntanetap critically important.

When was the patent for buntanetap in treating TBI filed?

The patent was initially filed in 2016 and has now been issued, specifically addressing the treatment of TBI and nerve injury with buntanetap.

What other conditions can buntanetap potentially treat?

Beyond TBI, buntanetap is aimed at treating various nerve injuries, including stroke and spinal cord injuries, as part of Annovis Bio’s diverse portfolio.

Where can I find more information about Annovis Bio and its developments?

More information is available in the company’s newsroom at https://ibn.fm/ANVS and through specialized communications platforms like BioMedWire.

Who is involved in the development of buntanetap?

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, is behind the development of buntanetap for treating TBI and other neurodegenerative conditions.

What are the implications of this patent for patients with TBI?

This patent represents a promising advancement in the treatment of TBI, offering hope for reducing the high rates of death and disability associated with the condition through targeted therapy.